Cargando…

In Vitro and in Vivo Efficacy of NBDHEX on Gefitinib-resistant Human Non-small Cell Lung Cancer

Gefitinib, a first-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), is recommended for treatment of non-small cell lung cancer (NSCLC) patients who harbor activating EGFR mutations. However, the tumors of most patients initially sensitive to gefitinib will develop resistance within several mont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sha, Huanhuan, Dong, Shuchen, Yu, Chen, Zou, Renrui, Zhu, Yue, Lu, Ya, Zhang, Junying, Cao, Haixia, Chen, Dan, Wu, Jianzhong, Feng, Jifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646187/ https://www.ncbi.nlm.nih.gov/pubmed/33193885 http://dx.doi.org/10.7150/jca.46461

Ejemplares similares

NBDHEX re‐sensitizes adriamycin‐resistant breast cancer by inhibiting glutathione S‐transferase pi
por: Sha, Huanhuan, et al.
Publicado: (2022)

Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro
por: Hu, Yong, et al.
Publicado: (2017)

Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer
por: Sha, Huanhuan, et al.
Publicado: (2021)

Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro
por: Lou, Rui, et al.
Publicado: (2019)

LXR ligands induce apoptosis of EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt-NF-κB activation
por: Liu, Siwen, et al.
Publicado: (2018)

Research Progress on Mono-ADP-Ribosyltransferases in Human Cell Biology
por: Gan, Yujie, et al.
Publicado: (2022)

Cytokine-induced killer cells as a feasible adoptive immunotherapy for the treatment of lung cancer
por: Chen, Dan, et al.
Publicado: (2018)

Aldolase A Promotes Colorectal Cancer Progression through Targeting COPS6 and Regulating MAPK Signaling Pathway
por: Lu, Ya, et al.
Publicado: (2023)

MicroRNA‐381 in human cancer: Its involvement in tumour biology and clinical applications potential
por: Sha, Huanhuan, et al.
Publicado: (2022)

Proteomic and functional analyses reveal pleiotropic action of the anti-tumoral compound NBDHEX in Giardia duodenalis
por: Camerini, Serena, et al.
Publicado: (2017)

CRNDE mediated hnRNPA2B1 stability facilitates nuclear export and translation of KRAS in colorectal cancer
por: Lu, Ya, et al.
Publicado: (2023)

The Nitrobenzoxadiazole Derivative NBDHEX Behaves as Plasmodium falciparum Gametocyte Selective Inhibitor with Malaria Parasite Transmission Blocking Activity
por: Siciliano, Giulia, et al.
Publicado: (2022)

In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer
por: Ni, Xiao Ling, et al.
Publicado: (2017)

Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib‐resistant lung adenocarcinoma cells
por: Ni, Jie, et al.
Publicado: (2018)

Cancer-associated changes of emotional brain network in non-nervous system metastatic non-small cell lung cancer patients: a structural connectomic diffusion tensor imaging study
por: Liu, Siwen, et al.
Publicado: (2020)

CRNDE: an oncogenic long non-coding RNA in cancers
por: Lu, Ya, et al.
Publicado: (2020)

Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin
por: Hu, Yong, et al.
Publicado: (2017)

Circulating tumor DNA detection: A potential tool for colorectal cancer management
por: Li, Huizi, et al.
Publicado: (2019)

The FAD-dependent glycerol-3-phosphate dehydrogenase of Giardia duodenalis: an unconventional enzyme that interacts with the g14-3-3 and it is a target of the antitumoral compound NBDHEX
por: Lalle, Marco, et al.
Publicado: (2015)

Nedaplatin reduces multidrug resistance of non-small cell lung cancer by downregulating the expression of long non-coding RNA MVIH
por: Jing, Changwen, et al.
Publicado: (2020)

miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer
por: Ge, Peng, et al.
Publicado: (2019)

The somatic mutation landscape of Chinese Colorectal Cancer
por: Ma, Rong, et al.
Publicado: (2020)

TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non–small‐cell lung cancer
por: Shuai, Shuai, et al.
Publicado: (2021)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

CDCA4 suppresses epithelial–mesenchymal transtion (EMT) and metastasis in Non-small cell lung cancer through modulating autophagy
por: Xu, Chenxin, et al.
Publicado: (2021)

A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization
por: Kola Srinivas, Navya Sree, et al.
Publicado: (2016)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Lansoprazole Alone or in Combination With Gefitinib Shows Antitumor Activity Against Non-small Cell Lung Cancer A549 Cells in vitro and in vivo
por: Zhao, Xiaoxia, et al.
Publicado: (2021)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

Comparison of nedaplatin-based versus cisplatin-based chemotherapy for advanced non-small cell lung cancer among East Asian populations: A meta-analysis
por: Liu, Yun, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer
por: Zou, Zheng-Zhi, et al.
Publicado: (2015)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

CLASRP oncogene as a novel target for colorectal cancer
por: Gu, Quan, et al.
Publicado: (2023)

Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer
por: Lu, Xiangdong, et al.
Publicado: (2021)

Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo
por: Yang, Sheng-Huei, et al.
Publicado: (2015)

Autophagy inhibitor facilitates gefitinib sensitivity in vitro and in vivo by activating mitochondrial apoptosis in triple negative breast cancer
por: Liu, Zhaoyun, et al.
Publicado: (2017)

The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression: DUXAP10 contributes to gefitinib resistance by repressing OAS2
por: Ren, Shengnan, et al.
Publicado: (2022)

Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo
por: Li, Tao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bcj957griesjrijmvavqraielk